Sol-Gel Technologies (SLGL) Payables (2016 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Payables of $782000.0 for Q1 2026, up 78.54% year-over-year from $438000.0 in Q1 2025, and up 6.39% quarter-over-quarter from $735000.0 in Q4 2025.
Sol-Gel Technologies (SLGL) Payables (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Payables for 11 consecutive years, with $782000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables rose 78.54% year-over-year to $782000.0; the TTM figure through Mar 2026 stood at $782000.0 (up 78.54% YoY), while the FY2025 annual figure was $735000.0, down 79.53% from the prior year.
- Payables advanced to $782000.0 in Q1 2026 per SLGL's latest filing, from $735000.0 in the prior quarter.
- Across five years, Payables topped out at $3.9 million in Q4 2023 and bottomed at $167000.0 in Q3 2022.
- Historically, Payables has averaged $1.0 million across 5 years, with a median of $735000.0 in 2025.
- Annual changes were most pronounced in 2022 — Payables slumped 97.53% — and 2023, when it soared 1462.15%.
- Sol-Gel Technologies' Payables stood at $251000.0 in 2022, then jumped by 1462.15% to $3.9 million in 2023, then retreated by 8.44% to $3.6 million in 2024, then sank by 79.53% to $735000.0 in 2025, then rose by 6.39% to $782000.0 in 2026.
- Business Quant data shows SLGL's Payables at $782000.0 in Q1 2026, $735000.0 in Q4 2025, and $828000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | 782,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 782,000.00 |
| Dec 31, 2025 | 735,000.00 |
| Sep 30, 2025 | 828,000.00 |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | 438,000.00 |
| Dec 31, 2024 | 3.59 Mn |
| Sep 30, 2024 | 1.52 Mn |
| Jun 30, 2024 | 679,000.00 |
| Mar 31, 2024 | 582,000.00 |
| Dec 31, 2023 | 3.92 Mn |
| Sep 30, 2023 | 234,000.00 |
| Jun 30, 2023 | 461,000.00 |
| Mar 31, 2023 | 339,000.00 |
| Dec 31, 2022 | 251,000.00 |
| Sep 30, 2022 | 167,000.00 |
| Jun 30, 2022 | 860,000.00 |
| Mar 31, 2022 | 1.11 Mn |
| Dec 31, 2021 | 10.15 Mn |
| Sep 30, 2021 | 1.29 Mn |
| Jun 30, 2021 | 1.35 Mn |